Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Cevostamab |
Synonyms | |
Therapy Description |
Cevostamab (BFCR4350A) is a bispecific antibody that targets both FCRH5 and CD3, potentially resulting in increased anti-tumor immune response and tumor cell killing (Blood (2020) 136 (Supplement 1): 42-43). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cevostamab | RO7187797|BFCR4350A | CD3 Antibody 99 | Cevostamab (BFCR4350A) is a bispecific antibody that targets both FCRH5 and CD3, potentially resulting in increased anti-tumor immune response and tumor cell killing (Blood (2020) 136 (Supplement 1): 42-43). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05801939 | Phase II | Cevostamab | Cevostamab Following CAR T Cell Therapy for RRMM | Recruiting | USA | 0 |
NCT03275103 | Phase I | Cevostamab | Dose-Escalation Study of BFCR4350A in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) | Recruiting | USA | ESP | CAN | AUS | 0 |